Approved drugs that make cells clear out faulty mitochondria did not restore their energy
A screen of 1,971 approved medicines in cultured cells found nine that speed up the recycling of damaged mitochondria without harming the cells. But the two best candidates did not improve energy production in cells from patients with mitochondrial disease. A preprint, in cells only.
Mitochondria, the small power plants inside our cells, wear out. Cells deal with this by wrapping damaged ones in a membrane and sending them to the lysosome, the cell's recycling centre, to be broken down. This clean-up process is called mitophagy, a specialised form of autophagy. It tends to slow down with age, and drugs that boost it are of great interest both for aging research and for rare inherited mitochondrial diseases, in which faulty mitochondria cannot make enough energy.
Researchers have now screened nearly 2,000 medicines that are already approved in the United States, looking for ones that switch on mitophagy. The study is a preprint: it has not yet been peer-reviewed. Everything was done in cells grown in dishes.
What they did
The screen targeted a protein called TFEB, a master switch that, when it moves into the cell's nucleus, turns on genes for autophagy and for making new lysosomes. The researchers used fibroblasts (the cells that make connective tissue) taken from mice and engineered to glow, so that a microscope and software could count, cell by cell, whether TFEB had moved into the nucleus and how many mitochondria were being digested.
They tested 1,971 approved drugs this way. Drugs that killed too many cells were dropped. The rest were checked for whether they increased mitophagy without simply damaging mitochondria, because a poison can also trigger mitophagy, just for the wrong reason.
The best candidates were then tested in skin fibroblasts from patients whose mitochondria have one of two inherited defects (in parts of the energy-making chain called complex I and complex IV), and in cells from healthy people.
What they found
- Many drugs moved the switch, few passed every test. 294 drugs pushed TFEB into the nucleus. About half of those (147) were not too toxic, and nine of them increased mitophagy without breaking up or draining the mitochondria.
- Two front-runners. In the patients' cells, meptazinol, an opioid painkiller, gave the largest rise in mitophagy in the complex I cells (38.5% above untreated cells), and ponatinib, a leukaemia drug, in the complex IV cells (18.7%). The team notes that neither difference was statistically significant when all the drugs were compared together; the two were picked for the size of the effect.
- Different routes. Ponatinib appeared to work through mTOR, the cell's growth controller, which normally holds TFEB back, and it increased the number of lysosomes. Meptazinol acted without touching mTOR, and in the complex I cells it did not move TFEB at all.
- No energy rescue. Neither drug improved oxygen use or energy (ATP) production in the patients' cells. Ponatinib even reduced the energy the complex IV cells got from breaking down sugar, a backup supply these cells depend on.
What to keep in mind
- Cells only, and a preprint. Nothing here was tested in animals or people.
- Clearing is not repairing. The authors' explanation is that new mitochondria carry the same genetic fault, so faster turnover alone does not fix the energy problem. They suggest combining mitophagy with ways to build new mitochondria or to fix the energy chain directly.
- Small effects, few cell lines. The increases in mitophagy in patients' cells were modest and not statistically significant across all drugs, and each defect was studied in cells carrying one specific gene mutation.
- These are serious medicines. Meptazinol is a prescription opioid painkiller. Ponatinib is a prescription cancer drug with significant side effects, and in this study it was not neutral for the cells' energy supply.
Why it matters
Boosting mitophagy is often described as a way to slow aspects of aging. This study shows a careful way to find drugs that boost the clean-up without damaging the cell, and it gives the field a list of candidates to test further. Its sobering finding is that, at least in cells with a built-in mitochondrial defect, more clean-up did not mean more energy.